Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lowered its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 3.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,615 shares of the biopharmaceutical company’s stock after selling 1,735 shares during the quarter. State of New Jersey Common Pension Fund D owned about 0.08% of Celldex Therapeutics worth $1,788,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Celldex Therapeutics in the 2nd quarter worth approximately $76,000. CANADA LIFE ASSURANCE Co boosted its position in shares of Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 955 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 1,582 shares in the last quarter. Quest Partners LLC raised its holdings in shares of Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 6,879 shares during the period. Finally, Los Angeles Capital Management LLC lifted its stake in Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 638 shares in the last quarter.

Insider Activity at Celldex Therapeutics

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the business’s stock in a transaction on Monday, November 11th. The shares were bought at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Citigroup started coverage on Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, November 7th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. The Goldman Sachs Group began coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Down 1.0 %

Shares of Celldex Therapeutics stock opened at $23.31 on Tuesday. The firm has a market capitalization of $1.55 billion, a P/E ratio of -9.16 and a beta of 1.60. Celldex Therapeutics, Inc. has a 52 week low of $22.93 and a 52 week high of $53.18. The firm’s 50 day moving average is $31.89 and its two-hundred day moving average is $35.39.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.